Unicycive Therapeutics Files 8-K
Ticker: UNCY · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1766140
| Field | Detail |
|---|---|
| Company | Unicycive Therapeutics, Inc. (UNCY) |
| Form Type | 8-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Unicycive Therapeutics filed an 8-K for an 'Other Event' on Aug 15, 2025. Details TBD.
AI Summary
On August 15, 2025, Unicycive Therapeutics, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, but it confirms the company's status and reporting obligations. The company is incorporated in Delaware and its principal executive offices are located at 4300 El Camino Real, Suite 210, Los Altos, CA 94022.
Why It Matters
This filing indicates a material event has occurred that requires disclosure to the public, though the specifics are not yet detailed in this initial report.
Risk Assessment
Risk Level: medium — The filing is an 8-K for an 'Other Event' which suggests a material development, but the lack of specific details in this initial report creates uncertainty.
Key Players & Entities
- Unicycive Therapeutics, Inc. (company) — Registrant
- August 15, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 4300 El Camino Real, Suite 210, Los Altos, CA 94022 (address) — Principal executive offices
- (650) 351-4495 (phone_number) — Registrant's telephone number
FAQ
What specific event is Unicycive Therapeutics, Inc. reporting in this 8-K filing?
The filing is an 8-K for an 'Other Event' and does not specify the nature of the event in the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on August 15, 2025.
In which state is Unicycive Therapeutics, Inc. incorporated?
Unicycive Therapeutics, Inc. is incorporated in Delaware.
What is the address of Unicycive Therapeutics, Inc.'s principal executive offices?
The principal executive offices are located at 4300 El Camino Real, Suite 210, Los Altos, CA 94022.
What is the registrant's telephone number?
The registrant's telephone number is (650) 351-4495.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 14.4 · Accepted 2025-08-18 16:17:31
Filing Documents
- ea0253753-8k_unicycive.htm (8-K) — 23KB
- 0001213900-25-077937.txt ( ) — 185KB
- uncy-20250815.xsd (EX-101.SCH) — 3KB
- uncy-20250815_lab.xml (EX-101.LAB) — 33KB
- uncy-20250815_pre.xml (EX-101.PRE) — 22KB
- ea0253753-8k_unicycive_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 15, 2025, Unicycive Therapeutics, Inc. (the "Company") became aware of a lawsuit purporting to be a securities class action which was filed in United States District Court for the Northern District of California against the Company and certain of its officers. This action alleges violations of the federal securities laws in connection with public statements by the Company relating to its new drug application for oxylanthanum carbonate phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The Company believes the claims are meritless and intends to vigorously defend the lawsuit. - 1 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 18, 2025 UNICYCIVE THERAPEUTICS, INC. By: /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer - 2 -